Reports
Sale
Global Allergic Conjunctivitis Treatment Market Share, Size, Trends, Analysis, Growth, Forecast: By Diagnosis: Allergy Skin Test, Blood Test, Others; By Drug Class: Antihistamines and Mast Cell Stabilisers, Corticosteroids, NSAIDS, Others; By Disease Type; By Treatment Channel; Regional Analysis; Market Dynamics; Competitive Landscape; 2024-2032
Global Allergic Conjunctivitis Treatment Market Outlook
The allergic conjunctivitis treatment market size was estimated to be worth USD 8 billion in 2023, driven by the increasing incidences of ocular injuries. The market is expected to rise at a CAGR of 3.95% during the forecast period of 2024-2032. By 2032, the market value is anticipated to be worth USD 11.30 billion.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Allergic Conjunctivitis: Disease Insights
Allergic conjunctivitis is an ocular allergy caused by foreign agents like household dust, animal dander, pollen, chemical scents, or mould spores. The inflammation in the eye is caused due to an allergic reaction to allergens. Depending on the duration, allergic conjunctivitis can be of two types: Acute and Chronic.
Acute allergic conjunctivitis is the most common type and stays for a short term, while chronic one stays for a year or longer, and symptoms come and go as per the environmental conditions.
The human body produces a potent chemical, histamine in response to any foreign agents. As the allergens enter the eye, the body releases histamine as a defence mechanism. This leads to irritation, itching, and inflammation in the eye.
Diagnosis and Treatment Aiding the Allergic Conjunctivitis Treatment Market Growth
The diagnosis of the condition is done through eye monitoring and ophthalmological tests. An allergy skin test is also used to confirm the incidence of allergic conjunctivitis. The antibodies produced by the body are detected through blood tests. This is also an effective diagnostic procedure for allergic conjunctivitis disease.
There are no specific treatment guidelines for the management of allergic conjunctivitis. Home care remedies include washing the eyes and applying a cool compress to the eyes. In case of a severe problem, medications are used for the treatment. The anti-histaminic drugs, anti-inflammatory eye drugs, or eye drops can be used to alleviate allergic symptoms.
According to this study, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis
- Allergy Skin Test
- Blood Test
- Others
Market Breakup by Drug Class
- Antihistamines and Mast Cell Stabilisers
- Corticosteroids
- NSAIDS
- Others
Market Breakup by Disease Type
- Seasonal Allergic Conjunctivitis
- Contact Conjunctivitis
- Giant Papillary Conjunctivitis
- Perennial Conjunctivitis
- Vernal Keratoconjunctivitis
- Atopic Keratoconjunctivitis
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Allergic Conjunctivitis Treatment Market Scenario
The increase in the incidence of ocular allergies is the primary reason for market development. Due to rapid urbanisation and rising allergens, the susceptibility to allergic conjunctivitis increases. This is driving the growth of the market.
Increasing awareness has led to more adoption of medications and drugs for the management of ophthalmological problems. This has facilitated the demand of the treatment market. Easy availability and accessibility have also been attributed to the increased allergic conjunctivitis treatment market growth.
Increased investments in research and developmental activities, a major influx of generic drugs and a rising population, are some of the additional factors contributing to the growth of the market.
Antihistamines Account for the Largest Share
Among the drug classes, antihistamines are anticipated to have the largest share in the allergic conjunctivitis treatment market. Antihistamines and mast cell stabilizers are the cornerstone therapy for the management of allergic problems. Novel product launches in this drug class are also expected to boost the growth of the market during the forecast period.
Regional Outlook: North America, Europe, and the Asia Pacific Possess Significant Shares
North America is expected to have the greatest share in the market owing to the increased prevalence, greater awareness, and presence of significant key players in that region.
Following North America, Europe is projected to dominate among all the regional markets. The factors contributing to this share are more usage of sophisticated medications and the rising patient population.
The Asia Pacific region is anticipated to be the fastest-growing region in the allergic conjunctivitis treatment market. This is attributed to the raising awareness and significant improvements in the healthcare sector.
Therapeutic Landscape
Allergic Conjunctivitis is caused due to the overreaction of the immune system of the body towards an allergic response. There are different therapeutic options for the management of allergic conjunctivitis depending on the type and severity of the allergy. A major part of therapeutic interventions is also used as a precautionary measure against environmental allergies.
Drug Treatment: Antihistamines, Mast Cell Stabilisers, and Corticosteroids
Antihistamines, mast cell stabilisers, and corticosteroids are used to treat allergic symptoms. Drug treatment is the first line of treatment for allergic conjunctivitis. Antihistamines block the secretion of histamines, which are released due to the reaction of an immune system. Oral histamines and eye drops are the two forms of administration. Examples of antihistamines are cetirizine, loratadine, ketotifen and azelastine.
Mast cell stabilisers stabilise the mast cells and take a bit longer time to show their effect. These medications are administered in the form of eye drops. The most used mast cell stabilisers are nedocromil and lodoxamide.
Corticosteroids are only used in case of severe symptoms. These medications reduce inflammation and help in lowering the body’s immune response. These drugs should be used in short term due to their side effects.
There are other additional treatments used for alleviating symptoms. Artificial tears are the oral eye drops used to dilute the allergen and help in its elimination. Cold compresses are applied to provide a soothing effect to the eye and provides a relaxing effect.
Clinical Trials
The currently available medications and therapeutic interventions are optimal for the management of allergic conjunctivitis. However, preclinical, and clinical studies are under process to discover novel medications that are more effective and have lesser side effects.
Undergoing Clinical Trials are Anticipated to Boost the Allergic Conjunctivitis Treatment Market Growth
Topical steroids are commonly used for managing allergic symptoms. Clinical trials are being done for ester-based steroids, which are anticipated to have fewer adverse effects and better therapeutic potential. Mapracorat is presently under clinical studies. It reduces the uptake of eosinophils and helps in reducing inflammation.
Cyclosporine A is currently under clinical trials for assessing its efficacy and other side effects. The discovery of cyclosporine will reduce the reliance on topical steroids. Clinical studies are under process for determining the optimal cyclosporin concentration for distinct types of allergic conjunctivitis. Researchers are also conducting pre-clinical studies to check drug safety in the paediatric population.
Japan is conducting clinical trials for the ophthalmic application of calcineurin inhibitors. Tacrolimus eye drops are under research and have shown promising results in the early phases of clinical testing. This medication is under advanced testing for further evaluation.
The discovery of these novel therapeutic interventions will assist in the proper diagnosis and treatment of allergic conjunctivitis. The novel product launches will facilitate the expansion of the market.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the allergic conjunctivitis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Sun Pharmaceutical Industries Limited
- Novartis AG
- Bausch & Lomb
- AbbVie Inc.
- Ocular Therapeutix, Inc.
- Alexion Pharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Alembic Pharmaceuticals Ltd.
- Grevis Pharmaceuticals Pvt. Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
| Breakup by Drug Class |
|
| Breakup by Disease Type |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Allergic Conjunctivitis Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Allergic Conjunctivitis Treatment Market
8.1 Global Allergic Conjunctivitis Treatment Market Overview
8.2 Global Allergic Conjunctivitis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Allergic Conjunctivitis Treatment Market Historical Value (2017-2023)
8.2.1.2 Global Allergic Conjunctivitis Treatment Market Forecast Value (2024-2032)
8.3 Global Allergic Conjunctivitis Treatment Market by Diagnosis
8.3.1 Market Overview
8.3.1.1 Allergy Skin Test
8.3.1.2 Blood Test
8.3.1.3 Others
8.4 Global Allergic Conjunctivitis Treatment Market by Drug Class
8.4.1 Market Overview
8.4.1.1 Antihistamines and Mast Cell Stabilisers
8.4.1.2 Corticosteroids
8.4.1.3 NSAIDS
8.4.1.4 Others
8.5 Global Allergic Conjunctivitis Treatment Market by Disease Type
8.5.1 Market Overview
8.5.1.1 Seasonal Allergic Conjunctivitis
8.5.1.2 Contact Conjunctivitis
8.5.1.3 Giant Papillary Conjunctivitis
8.5.1.4 Perennial Conjunctivitis
8.5.1.5 Vernal Keratoconjunctivitis
8.5.1.6 Atopic Keratoconjunctivitis
8.6 Global Allergic Conjunctivitis Treatment Market by Treatment Channel
8.6.1 Market Overview
8.6.1.1 Public
8.6.1.2 Private
8.7 Global Allergic Conjunctivitis Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Middle East and Africa
8.7.1.5 Latin America
9 North America Allergic Conjunctivitis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Allergic Conjunctivitis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Allergic Conjunctivitis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Allergic Conjunctivitis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Allergic Conjunctivitis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Allergic Conjunctivitis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sun Pharmaceutical Industries Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Bausch & Lomb
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 AbbVie Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Ocular Therapeutix, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Alexion Pharmaceuticals Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Santen Pharmaceutical Co., Ltd.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Dr. Reddy’s Laboratories Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Alembic Pharmaceuticals Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Grevis Pharmaceuticals Pvt. Ltd.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Allergic Conjunctivitis Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 8 billion in 2023, driven by the rising incidences of ocular injuries.
The market is projected to grow at a CAGR of 3.95% during the forecast period of 2024-2032 to achieve a value of USD 11.30 billion by 2032.
Allergic conjunctivitis is an ocular allergy caused by foreign agents like household dust, animal dander, pollen, chemical scents, or mould spores.
Corticosteroids, antihistamines, and mast cell stabilisers are the primary drugs used to manage allergic conjunctivitis.
Based on the drug class, the market is segmented into antihistamines and mast cell stabilizers, corticosteroids, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa.
The two types of allergic conjunctivitis are acute and chronic.
The treatment channels in the market are public and private.
Increasing incidence of ocular allergies, raising awareness and growing investments in the research and development sector are the driving factors in the market.
North America is anticipated to hold a significant share in the market during the forecast period.
The key companies involved in the market are Sun Pharmaceutical Industries Limited, Novartis AG, Bausch & Lomb, AbbVie Inc., Ocular Therapeutix, Inc., Alexion Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Ltd., and Grevis Pharmaceuticals Pvt. Ltd., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER